Structure-Based Rational Design of a Toll-like Receptor 4 (TLR4) Decoy Receptor with High Binding Affinity for a Target Protein by Han, Jieun et al.
Structure-Based Rational Design of a Toll-like Receptor 4
(TLR4) Decoy Receptor with High Binding Affinity for a
Target Protein
Jieun Han
1., Hyun Jung Kim
2,3., Sang-Chul Lee
1¤, Seungpyo Hong
4, Keunwan Park
4, Young Ho Jeon
2,
Dongsup Kim
4, Hae-Kap Cheong
2*, Hak-Sung Kim
1,5*
1Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), Yuseong-gu, Daejeon, Korea, 2Division of Magnetic Resonance
Research, Korea Basic Science Institute, Cheongwon, Chungbuk, Korea, 3College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk, Korea, 4Department
of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology (KAIST), Yuseong-gu, Daejeon, Korea, 5Graduate School of Nanoscience and
Technology, Korea Advanced Institute of Science and Technology (KAIST), Yuseong-gu, Daejeon, Korea
Abstract
Repeat proteins are increasingly attracting much attention as alternative scaffolds to immunoglobulin antibodies due to
their unique structural features. Nonetheless, engineering interaction interface and understanding molecular basis for
affinity maturation of repeat proteins still remain a challenge. Here, we present a structure-based rational design of a repeat
protein with high binding affinity for a target protein. As a model repeat protein, a Toll-like receptor4 (TLR4) decoy receptor
composed of leucine-rich repeat (LRR) modules was used, and its interaction interface was rationally engineered to increase
the binding affinity for myeloid differentiation protein 2 (MD2). Based on the complex crystal structure of the decoy
receptor with MD2, we first designed single amino acid substitutions in the decoy receptor, and obtained three variants
showing a binding affinity (KD) one-order of magnitude higher than the wild-type decoy receptor. The interacting modes
and contributions of individual residues were elucidated by analyzing the crystal structures of the single variants. To further
increase the binding affinity, single positive mutations were combined, and two double mutants were shown to have about
3000- and 565-fold higher binding affinities than the wild-type decoy receptor. Molecular dynamics simulations and
energetic analysis indicate that an additive effect by two mutations occurring at nearby modules was the major contributor
to the remarkable increase in the binding affinities.
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Introduction
Repeat proteins, which are composed of varying numbers of
repeating modules (units), have been identified in a variety of
functionally related proteins, and their modular architecture was
shown to evolve to be suitable for protein-protein interactions
[1,2,3]. Leucine-rich repeat (LRR) proteins, a typical repeat
protein, are characterized by an assembly of consecutive LRR
modules that represent the b strand-turn-a helix structure [4,5,6].
Repeat modules stack in a relatively linear manner to form an
elongated modular architecture that has a horseshoe shape,
providing large interaction surfaces. LRR proteins mediate many
important biological functions including cell adhesion, signaling
processes, neural development, bacterial pathogenicity, extracel-
lular matrix assembly, and immune response [7,8]. Typical LRR
proteins include the mammalian ribonuclease inhibitor [9], Toll-
like receptors (TLRs) [10], bacterial internalins [11,12], plant
disease-resistance R proteins, and variable lymphocyte receptors
(VLRs) from jawless fish. With unique structural features, repeat
proteins have increasingly attracted much attention as alternative
scaffolds to immunoglobulin antibodies to generate molecular
binders for use in biotechnology and biomedical fields [13–18].
Toll-like receptor 4 (TLR4), a superfamily of LRR proteins, is
the principal receptor mediating innate immune responses against
infections by Gram-negative bacteria [19,20,21]. In this process,
myeloid differentiation protein 2 (MD2) recognizes various
lipopolysaccharides (LPSs) released from the Gram-negative
bacteria, forming a complex with LPS at its hydrophobic pocket
[22]. The resulting MD2/LPS complex triggers a TLR4-mediated
signaling process by binding to the TLR4 extracellular domain,
leading to nuclear factor-kB activation, which causes acute and
severe inflammation and sepsis. In an attempt to prevent the
systemic immune response caused by LPS, a TLR4 decoy receptor
was constructed by combining LRR modules from the TLR4
ectodomain and VLR [23]. The constructed decoy receptor was
shown to attenuate the TLR4-mediated signaling process by
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30929trapping MD2, implicating a potential therapeutics for bacteria-
induced sepsis and inflammation [24].
Design of a binding protein with high affinity and specificity for
a target ligand is prerequisite for the use in biotechnology and
biomedical fields, and many advances have been made [25,26].
Nonetheless, engineering interaction interfaces and understanding
molecular basis for affinity maturation of repeat proteins still
remains a challenge. Here, we present a structure-based rational
design of a repeat protein with high binding affinity for a target
protein. A TLR4 decoy receptor composed of hybrid LRR
modules was used as a model repeat protein, and its interaction
interface was rationally designed to increase the binding affinity
for MD2. Our strategy for increasing the binding affinity was to
strengthen the pre-existing interactions and to generate additional
intermolecular interactions with the target protein. Based on the
complex crystal structure of the decoy receptor with MD2, we first
designed single amino acid substitutions in the decoy receptor that
would lead to increased binding affinity for MD2. We selected
three of the variants showing a binding affinity (KD) one-order of
magnitude higher than the wild-type decoy receptor, and
determined their crystal structures to elucidate the interacting
modes and contributions of individual residues. To further
increase the binding affinity, single positive mutations were
combined, and two double mutants were shown to have
approximately 3000- and 565-fold higher binding affinities than
the wild-type decoy receptor. To understand the molecular basis
for a remarkable increase in the binding affinity, molecular
dynamics simulations and energetic analysis were conducted.
Results
Rational design of single variants with increased binding
affinity
To demonstrate a rational design of a repeat protein with high
binding affinity, we employed a TLR4 decoy receptor as a repeat
protein scaffold. This TLR4 decoy receptor was constructed by
combining LRR modules from human TLR4 ectodomain and
hagfish variable lymphocyte receptor (VLR) [23]. Overall
structure of the decoy receptor comprised an LRRNT, seven
LRR human TLR4 modules, and two LRRs, LRRCT of hagfish
VLRB. 61. Based on the crystal structure of the decoy receptor in
complex with MD2 (PDB ID 2Z65), we first attempted to identify
the interacting residues and potential interacting residues on the
decoy receptor that would increase the binding affinity toward
MD2. For this, we examined the residues at the interface, which
are located within 6 s distance from the MD2, and selected the 14
residues located at eight repeat modules. These residues were
expected to interact with Ile-66, Arg-68, Asp-99, Arg-106, Leu-
108, Lys-109, and Glu-111 on MD2 (Figure 1). We adopted two
approaches to design the decoy receptor variants with higher
binding affinity for MD2: one was to strengthen the pre-existing
interactions, and the other was to generate additional interactions
by mutating the potential interaction residues based on the
following analysis.
Hydrophobic interactions. By considering the size and
hydrophobic index of each amino acid residue, we determined the
substituting residues leading to increased hydrophobic interaction.
Changing phenylalanine at position 63 was likely to form a
hydrophobic interaction with Ile-66 of MD2 in the crystal
structure of the decoy receptor/MD2 complex. Phe-63 was
substituted for tryptophan and leucine for the interaction with
Ile-66 in MD2. Analysis of the interaction interface inferred that
four residues (Thr-110, Val-132, Val-134, and Asn-156) on the
decoy receptor were in position to make additional hydrophobic
interactions with Leu-108 of MD2 when substituted for larger
amino acid residues. Replacement of these four residues with more
hydrophobic residues was expected to generate additional
hydrophobic interactions with Leu-108 on MD2, consequently
resulting in an increase in MD2 binding affinity. Specifically,
replacing Thr-110 with more hydrophobic residues such as
isoleucine, leucine, phenylalanine, or tyrosine would generate
additional interactions. In the case of Val-132 and Val-134,
replacing these residues with phenylalanine or leucine might
create a strong hydrophobic interaction. Substituting Asn-156 for
isoleucine or phenylalanine appeared to produce an additional
hydrophobic interaction. To minimize the number of variants to
construct, the amino acid residue at each site was replaced with
one or two representative residues, except Thr-110.
Charge interactions. Analysis of the decoy receptor/MD2
complex structure indicated that the residues at positions 41, 62,
86, 158, 184, 284, and 285 on the decoy receptor were located
closely to the MD2 charged residues such as Arg-68, Asp-99, Lys-
109, and Glu-111. We reasoned that substituting these residues for
charged residues would increase the interaction with MD2 via
charge interactions. It is likely that the M41E and S62E mutations
would induce strong interactions with positively charged Arg-68
and Lys-109 of MD2. Additionally, replacing Ser-86 and Ala-158
with a negatively charged amino acid such as aspartic acid and a
positively charged residue such as lysine, respectively, would
generate additional charge interactions with Lys-109 and Glu-111
of MD2. Changing Ser-184 to glutamate or lysine was expected to
form a strong interaction with Arg-106 and Glu-111 on MD2.
Finally, mutating Gln-284 and Gly-285 to lysine would yield a
charge interaction with Asp-99 of MD2.
Hydrogen bonds. From the crystal structure of the decoy
receptor/MD2 complex, Ser-183 and Asp-209 on the decoy
receptor had a hydrogen bond with Arg-106 of MD2.
Furthermore, Asp-181 of the decoy receptor was located within
a5s from the Arg-106 of MD2, possibly producing an additional
hydrogen bond. Replacing Asp-181 with a residue containing a
long side chain such as glutamate would induce a hydrogen bond.
Changing Val-134 and His-159 to residues with polar side chains
such as asparagine and glutamine was predicted to yield additional
hydrogen bonding with Glu-111 of MD2. Changing Ala-158 to
phenylalanine appeared to strengthen a hydrogen bond between
His-159 of decoy receptor and Glu-111 on MD2 by filling the
vacant space between the two residues.
Construction of single variants
Based on the decoy receptor designs described above, we
constructed 22 single mutants by replacing the residues at 14 sites
on the decoy receptor with one or two residues (Table S1). We
first checked the expression of each variant, and observed that the
expression levels of variants generally decreased compared to the
wild-type decoy receptor. Nine of 22 single variants showed
relatively high expression levels, including M41E, F63L, F63W,
V132F, V134L, N156I, H159Q, D181E, and S184K. Dissociation
constants (KD) of the selected variants for MD2 were determined
using surface plasmon resonance (SPR) analysis. Typical senso-
grams of the wild-type decoy receptor and its variants are shown in
Figure S1, and their KD values are listed in Table 1. Of nine
single mutants tested, eight exhibited increased affinity, and one
had slightly decreased affinity for MD2. Interestingly, five single
mutants (M41E, F63W, V134L, N156I, and H159Q) displayed
binding affinities one-order of magnitude higher than that of the
wild-type decoy receptor. This result strongly implied that our
design strategy worked well and was reasonable.
Rational Design of a TLR4 Decoy Receptor
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To get detailed information on interacting interfaces, we
attempted to determine the crystal structures of three single
variants (M41E, F63W, V134L) in complex with MD2 in the
presence of Eritoran. It was shown that Eritoran, derived from the
lipid A structure of Rhodobacter sphaeroides LPS, is critical for
crystallizing the decoy receptor/MD2 complex [23]. We obtained
the crystals of three mutants in complex with MD2 and Eritoran.
The F63W mutant /MD2 complex structure was determined at a
3.6 A ˚ resolution and the others at lower resolution. Even at this
moderately low resolution, the density maps clearly reveal
backbone structure and some side chains. Especially, we could
determine the side chain position of the mutated F63W residue
and interaction with Arg-68 of MD2. Superposition of the crystal
structure of the mutants in complex with MD2 and Eritoran on
the crystal structure of the wild-type decoy receptor/MD2/
Eritoran complex resulted in a Ca r.m.s.d of 0.45 A ˚ for all atoms
(Figure 2A). MD2 bound to the concave surface derived from the
‘‘LxLxxN’’ parts of the LRR modules in the mutants. Eritoran
bound to MD2 in a similar manner to the wild-type decoy
receptor/MD2/Eritoran complex. From the complex structure of
F63W mutant, we confirmed that the mutated Trp-63 was
positioned to interact directly with Arg-68 of MD2 and the
guanido group of Arg-68 on MD2 was placed between the indole
Figure 1. Identification of the mutation sites on the decoy receptor, TV3, for constructing single variants. (A) Crystal structure of the
decoy receptor in complex with MD2 (PDB ID 2Z65). The decoy receptor and MD2 are shown as green and yellow, respectively. (B) Structure of the
interaction interface. 14 identified residues in TV3 are indicated in green, and potential interaction residues in MD2 are represented in yellow.
doi:10.1371/journal.pone.0030929.g001
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group of Tyr-42 on MD2, creating an amino-aromatic (cation-p)
interaction (Figure 2B). The larger Trp-63 indole ring was able to
be properly positioned to form a cation-p interaction, whereas the
Phe-63 phenyl ring was too far from Arg-68 in the wild-type decoy
receptor/MD2 complex structure.
To analyze the interaction interfaces of other single mutants
(M41E and V134L), we obtained the modeled interaction
interfaces by superimposing their apo structures into the
complex structure of the wild-type decoy receptor/MD2. For
this, we determined the crystal structures of the single mutants in
free form at a 22.4 A ˚ resolution. As shown in Figure 3A,t h e
single mutants were well superimposed on the wild-type decoy
receptor, showing a Ca r.m.s.d of 0.4–0.5 A ˚,w h i c hi n d i c a t e st h a t
their original backbone structures were retained. The relative Cb
positions of the mutated residues were also well superposed on
those of the wild-type. The concave surface of the mutants
composed of seven parallel b strands remained unchanged as a
whole compared to the wild-type. In the M41E mutant, a
substituted glutamate residue was expected to interact with Lys-
109 of MD2, creating a salt-bridge (Figure 3B), whereas Met-41
in the wild-type decoy receptor had no specific interaction with
MD2. This salt bridge is likely to contribute to an increase in
binding affinity of the M41E mutant for MD2 by changing the
electrostatic property. In the V134L mutant, a substituted Leu-
134 residue was able to form a hydrophobic interaction with
Leu-108 on MD2 (Figure 3C). It seemed that the larger side
chain of Leu-134 had closer contact with Leu-108 on MD2
without a significant change in the backbone structure compared
with the wild-type decoy receptor in complex with MD2. To
validate the modeled interaction interfaces of the single mutants
(M41E and V134L), we also obtained the modeled interaction
interface of the F63W mutant with MD2 by superimposing the
crystal structure of apo F63W mutant into the wild-type decoy
receptor/MD2 complex as the M41E and V134L mutants. As
can be seen Figure 3D, the modeled interface structure of the
F63W mutant was well coincident with its crystal structure in
complex with MD2. This result strongly supports that the
modeled interaction interfaces of the M41E and V134L mutants
with MD2 are valid.
Construction and analysis of multiple mutants
Consecutive modules in repeat proteins are closely associated
with each other to form an elongated unique structure, providing a
large surface area for interaction with a target ligand. We reasoned
that multiple mutations over repeat modules of the decoy receptor
Table 1. Binding affinities of single mutants for MD2.
Mutant Ka (M
21 S
21)K d (S
21)K D (M)
Fold-
increase
Wild-type 2.8460.02610
4 2.2260.05610
23 7.8060.14610
28 1
M41E 1.6460.57610
4 5.2960.80610
25 3.2161.02610
29 24.3
F63L 2.6560.02610
4 1.1560.01610
23 4.3360.03610
28 1.8
F63W 1.3960.10610
4 3.9762.13610
25 2.8461.66610
29 27.5
V132F 6.9163.69610
4 1.5460.01610
23 2.2261.41610
28 3.5
V134L 2.6760.28610
4 1.1060.01610
24 4.1160.50610
29 19.0
N156I 1.9760.33610
4 8.0564.77610
25 4.0761.71610
29 19.2
H159Q 2.1461.21610
3 1.0060.44610
25 4.3063.23610
29 18.1
D181E 1.9160.10610
4 9.2461.35610
24 4.8260.44610
28 1.6
S184K 7.6660.02610
3 1.4160.02610
23 1.8360.04610
27 0.4
Binding affinities (KD) of the single mutants for MD2 were measured from the
association rate constants (Ka) and dissociation rate constants (Kd) using surface
plasmon resonance. Fold-increase represents the ratio of binding affinities
between the mutants and wild-type decoy receptor.
doi:10.1371/journal.pone.0030929.t001
Figure 2. Crystal structure of the F63W mutant in complex with
MD2. (A) Superimposed backbone structure of F63W mutant/MD2
complex into the wild-type decoy receptor/MD2 complex structure. The
F63W showed a slight movement toward the N-terminal direction by
0.4 A ˚ compared to the wild-type decoy receptor in complex with MD2.
(B) The complex structure of F63W mutant/MD2. The mutated Tyr-63
was closely located to Arg-68 on MD2, creating cation-p interaction. The
F63W mutant in complex structure is indicated as red and MD2 of
F63W/MD2 complex is colored in yellow. The electron density map of
mutant complex is shown as blue. (C) Comparison of the wild-type
decoy receptor/MD2 and F63W/MD2 complex structures. The key
residues and backbone structure of wild-type decoy receptor/MD2
complex are shown in grey. In F63W/MD2 complex, the F63W mutant is
shown in red, and MD2 in yellow, respectively.
doi:10.1371/journal.pone.0030929.g002
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in MD2 binding affinity. Based on the results of single mutants, 13
multiple mutants were constructed by combining single mutations;
12 double mutants and one triple mutant (Table S1). Of them, we
selected five double mutants showing a relatively high expression
level, and determined their binding affinities for MD2. As shown
in Table 2, two double mutants, M41E/F63W and V134L/
H159Q, displayed remarkably increased binding affinities for
MD2. Their KD values were estimated to be 26 pM and 138 pM,
which corresponded to approximately 3000- and 565-fold
increases compared to the wild-type (KD=78 nM), respectively
(Figure S1). Meanwhile, the F63W/D181E mutant exhibited a
comparable affinity (KD=39 nM) to the wild-type. Analysis of the
association and dissociation rate constants of the M41E/F63W
and V134L/H159Q mutants revealed that their association rate
constants (Ka) were almost comparable to the wild-type decoy
receptor. In contrast, their dissociation rate constants (Kd)
significantly decreased, which resulted in a remarkable increase
in the binding affinities of the mutants for MD2. This result
strongly supports the presumption that an appropriate combina-
tion of single mutations over individual modules of repeat proteins
would induce an additive effect on binding affinity. In particular, it
is noteworthy that mutations occurring at nearby modules resulted
in a notable increase in the interaction between the mutants and
MD2.
To gain some insight into the mechanism by which the binding
affinities of double mutants (M41E/F63W and V134L/H159Q)
significantly increased, we conducted molecular dynamics simu-
lations for the model structures of the double mutants in complex
with MD2 to analyze the interaction strengths and binding modes.
We attempted to determine the crystal structures of these mutants
in complex with MD2, but could not obtain the appropriate
complex crystals for a structural determination. Thus, we obtained
the model structures of the double mutants and used them for
molecular dynamics simulation. Only mutated residues were
subjected to binding energy calculations, because the energy
fluctuation in the system was too large to converge in a 5-ns time
scale. Based on the simulation results, we estimated the Coulomb
interactions and Lennard-Jones (LJ) potentials as well as the
number of hydrogen bonds between each double mutant and
MD2. Differences in the energy levels between respective mutants
Figure 3. Interface structures of single variants. (A) Superimposed backbone structures of the wild-type decoy receptor and three single
mutants (M41E, F63W, and V134L). (B) Interface structure of the M41E mutant obtained by superimposing the crystal structure of apo M41E mutant
into the wild-type decoy receptor/MD2 complex structure. Glu-41 was positioned to be able to form a salt-bridge with Lys-109 on MD2. The crystal
structure of the M41E is shown in blue, and the wild-type decoy receptor and MD2 are colored in green and yellow, respectively. (C) Interface
structure of the V134L mutant obtained by superimposing the crystal structure of apo V134L mutant into the wild-type decoy receptor/MD2 complex
structure. The larger Leu-134 is possible to make closer contact with Leu-108 on MD2. The crystal structure of the V134L is colored in orange (D)
Interface structure of the F63W mutant obtained by superimposing the crystal structure of apo F63W mutant into the wild-type decoy receptor/MD2
complex structure. The mutated Trp-63 was expected to create the amino-aromatic (cation-p) interaction of Tyr-42 and Arg-68. The crystal structure
of the F63W is shown in red.
doi:10.1371/journal.pone.0030929.g003
Table 2. Binding affinities of double mutants for MD2.
Mutant Ka (M
21 S
21)K d (S
21)K D (M)
Fold-
increase
Wild-type 2.8460.02610
4 2.2260.05610
23 7.8060.14610
28 1
M41E/F63W 2.0160.01610
4 5.2360.5610
27 2.6060.24610
211 3000
M41E/H159Q 3.1662.60610
3 4.6163.90610
24 1.4560.48610
27 0.5
F63W/V134L 3.6660.01610
3 1.0360.22610
23 2.8360.62610
27 0.3
F63W/D181E 5.8360.32610
2 2.2760.92610
25 3.9061.80610
28 2
V134L/H159Q 4.4160.60610
4 6.1261.11610
26 1.3860.06610
210 565
Fold-increase indicates the ratio of binding affinities between the mutants and
wild-type decoy receptor.
doi:10.1371/journal.pone.0030929.t002
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summarized in Table 3. For comparison, we performed the
same calculations for the single mutant crystal structures.
In the M41E/F63W double mutant showing a 3000-fold
increased binding affinity, the change in the Coulomb interaction
was dominant, as it increased by 150.41 kJ/mol, whereas a
negligible change (0.3 kJ/mol) in the LJ potential was observed
compared with the wild-type. In addition, the number of hydrogen
bonds increased by 2.53. However, the M41E mutant exhibited an
increase of 86.31 kJ/mol in the Coulomb interaction and a
decrease of the LJ potential by 4.53 kJ/mol, respectively. Thus, an
increase in the binding affinity of the M41E mutant was likely to
come mainly from the increased charge interaction. The F63W
mutant displayed increases in the Coulomb interaction and LJ
potential by 17.08 and 11.02 kJ/mol, respectively, indicating a
significant enhancement in the hydrophobic interaction, as
expected. Trp-63 concurrently contributed to an increase in the
charge interaction via additional hydrogen bonding with the
residues on MD2. Increases in the Coulomb interaction in the
double mutant (M41E/F63W) were much higher than those
obtained by summation of two single mutations, indicating that
two single mutations (M41E and F63W) are additive in an
interaction with MD2, resulting in a remarkable increase in
binding affinity.
As for the V134L/H159Q double mutant, the Coulomb
interaction and LJ potential were stabilized by 24.69 kJ/mol
and 20.71 kJ/mol, respectively, compared with those obtained by
adding two single mutations (V134L and H159Q). At the same
time, H159Q produced an increased number of hydrogen bonds
in the double mutant from 0.35 to 0.5, compared with the wild-
type decoy receptor. Although the increase in the Coulomb
interaction was relatively low, this mutant displayed a 565-fold
increase in binding affinity. Other factors contributing to the
increased binding affinity remain to be demonstrated. Unlike the
above two double mutants, combining F63W and D181E resulted
in a marginal increase in MD2 binding affinity, which seemed to
originate from the destabilized Coulomb interaction of 21.79 kJ/
mol and the destabilized LJ potential of 4.68 kJ/mol. Similar
results were observed in the MD simulations of the single mutant
crystal structures, which verifies that our simulations are
reasonable.
To obtain more detailed information about the additive effect
by two mutations on the binding affinity of the double mutant
(M41E/F63W) for MD2, we analyzed the effect of the F63W
mutation on the interaction of Glu-41 with water molecules in the
double mutant. The Coulomb interaction between Glu-41 and
water molecules in the double mutant was calculated and
compared with that of the M41E mutant. The energy levels
represented the changes from the wild-type. The Coulomb
interaction in the single mutant was approximately 2325.09 kJ/
mol, whereas the double mutant had a Coulomb interaction of
2190.80 kJ/mol. A significant decrease in the Coulomb interac-
tion in the double mutant reflected an increase in the interaction of
the mutant with MD2, which was caused by Trp-63. In other
words, replacement with a more hydrophobic residue (tryptophan)
at position 63 enhanced hydrophobicity, leading to exclusion of
water molecules, which consequently resulted in the reduced
Coulomb interaction with water molecules. At the same time, the
F63W mutation resulted in a subtle change in conformation,
enabling Glu-41 to form multiple interactions with the residues on
MD2. As shown in Figure 4A, Glu-41 in the double mutant
formed multiple interactions with Arg-68, Arg-69, and Lys-109 of
MD2. The structural analysis also revealed that the double mutant
(M41E/F63W) underwent a slight change in conformation
compared with the single M41E mutant. In this context, it is
evident that two single mutations (M41E and F63W) were
additive, yielding a 3000-fold increase in the binding affinity for
MD2. In the V134L/H159Q mutant, an increased hydrophobic
environment, resulting from V134L, enhanced the charge
interactions between Gln-159 and Glu-111 of MD2, reducing
the interactions with water molecules (Figure 4B). In contrast, in
the case of the F63W/D181E mutant, two single mutations were
located far apart; thus, the local hydrophobic effect from mutated
Trp-63 may have been very weak, resulting in a negligible effect
on the charge interaction by Glu-181. Additionally, this might
hinder the interaction between the mutated Glu-181 and Arg-106
of MD2, leading to a reduction in the number of hydrogen bonds,
DHB=21.18.
Discussion
We have demonstrated a structure-based rational design of the
TLR4 decoy receptor with high binding affinity for MD2. Design
of single substitutions based on the interaction interface generated
the single variants showing a considerable increase in binding
affinities compared with the wild-type decoy receptor. The crystal
structures of three single mutants revealed that mutated residues
have interactions with the target protein (MD2) as we designed,
which confirms that our design strategy works well. A significant
increase in the binding affinity was achieved by combining single
positive mutations, and double mutants (M41E/F63W and
V134L/H159Q) were shown to have about 3000- and 565-fold
increased binding affinities for the target, respectively. Molecular
dynamics simulations and energetic analysis of the double variants
indicated that an additive effect by two mutations occurring at
nearby modules plays a major role in a remarkable increase in the
binding affinity. A strong additive effect seems to result from
modular architecture of a repeat protein.
The crystal structures of the selected single mutants as apo and
complexed with MD2 provided detailed information on the
interaction modes of the residues at the interface and the
contribution of mutated residues to binding affinity. Superposition
of the mutants on the wild-type revealed that their original
Table 3. Changes in the interaction energies and hydrogen
bond numbers.
Mutants DCoulomb
*(kJ/mol) DLJ
*(kJ/mol) DHB
{
M41E 286.32 (248.14) 4.53 (5.14) 1.27 (0.63)
F63W 217.08 (3.82) 211.02 (22.08) 0.80 (0.04)
V134L 21.49 (21.38) 24.97 (21.80) 0 (0)
H159Q 226.10 3.93 0.35
D181E 29.00 0.60 0.38
M41E/F63W 2150.41 0.30 2.53
F63W/D181E 21.79 4.68 20.01
V134L/H159Q 232.28 21.75 0.50
*Differences in the interaction energies between the mutants and wild-type
decoy receptor (Emut-Ewild, kJ/mol) were calculated using Gromacs4 package
with an Amber03 force field. Each energy value represents the average of 3-ns
molecular dynamics trajectories.
{The number of hydrogen bonds was analyzed for each 3-ns molecular
dynamics trajectory snapshot, and differences in their average values between
the mutants and wild-type decoy receptor are shown as DHB.
Values in parenthesis were obtained by molecular dynamics simulations with
the crystal structures of the single mutants (M41E, F63W, and V134L).
doi:10.1371/journal.pone.0030929.t003
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characteristics of repeat proteins. The M41E mutant was designed
to have a strong charge interaction with a positively charged Lys-
109 in MD2 and the substituting Glu-41 was shown to be able to
form an additional interaction with Lys-109 of MD2, resulting in a
significant increase in binding affinity. From the structure of the
F63W and V134L mutants, it was expected that hydrophobic
interactions would increase by introducing a residue with a larger
hydrophobic side chain. The complex structure of the F63W
mutant displayed that Trp-63 was closely positioned to form a
cation-p interaction with Arg-68 on MD2, confirming our design
strategy. In the case of the V134L mutant, the larger Leu-134 was
able to have a strong hydrophobic interaction with Leu-108 on
MD2, which seemed to have a positive effect on binding affinity.
This result also validates our strategy for the design of variants
with high binding affinities for MD2. Molecular dynamics
simulations supported the above results as shown in Table 3.I n
the M41E and D181E mutants, substitutions strengthened the
Coulomb interactions. Both the F63W and V134L mutations were
designed to enhance hydrophobic interactions and MD simula-
tions confirmed increased LJ potentials. Interestingly, these
mutations were predicted to enhance the charge interactions as
well. The H159Q mutant was expected to have additional
hydrogen bonds with MD2 compared with the wild-type decoy
receptor. These results are coincident with the recent reports that
electrostatic interactions are significant in TLR4/MD2/LPS
signaling as well as in antagonist design related to TLR4 signaling
pathway [27,28].
Combining positive single mutations for further increasing the
binding affinity generated the double mutants (M41E/F63W and
V134L/H159Q) with about 3000- and 565-fold increased binding
affinities for the target, respectively. Interestingly, two mutations
occurred at nearby modules, and these mutations were shown to
be additive for increasing an interaction with the target. In other
words, Trp-63 enhanced the hydrophobic interaction, and this
mutation concurrently led to a significant increase in the Glu-41
charge interaction. In the simulation model, the mutated Glu-41
made a charge interaction with three residues (Arg-68, Arg-69,
and Lys-109 of MD2 (Figure 4A). Increasing the hydrophobic
interaction would create a more hydrophobic local environment,
excluding water molecules, which consequently would result in
much stronger Coulomb interactions between the mutant and the
target. Molecular dynamics simulations of the single and double
mutants also provided a detailed explanation on an additive effect
by two single mutations occurring at nearby modules. Interactions
between mutated polar residues and water molecules were
predicted to be significantly weakened by Trp-63. The V134L/
H159Q mutant also had a similar effect to the M41E mutant, even
though the change in the interaction with water molecules was not
as high as that of the M41E/F63W mutant. Thus, the closely
localized mutations effectively strengthened the hydrophobic and
charge interactions, inducing a significant additive effect.
In conclusion, we have demonstrated a successful design of the
TLR4 decoy receptor with high binding affinity for MD2 by a
rational approach. An additive effect by two mutations occurring
at nearby modules was shown to be a major contributor to the
remarkable increase in the binding affinity for the target. With
unique structural features such as modular architecture and rigid
backbone structure, repeat proteins have increasingly attracted
much attention as alternative scaffolds. In addition, they evolved to
be suitable for protein-protein interactions, mediating many
important biological functions in vivo. The present study will
provide some insights into designing repeat proteins with high
binding affinity and specificity as well as understanding the
molecular basis for protein-protein interactions.
Materials and Methods
Gene cloning and mutant construction
The gene encoding the TLR4 decoy receptor, TV3, was cloned
into the pAcGP67 vector (BD Biosciences) with the BamH I and
Not I sites. For protein purification, a thrombin cleavage site and
the Fc domain of human IgG were cloned into Not I and Bgl II of
the pAcGP67 vector containing the decoy receptor gene. The
human MD2 was cloned as the fused form with Protein A (GE
healthcare Life Sciences) into pAcGP67 vector using the same
restriction enzyme sites. For the removal of Protein A tag, the
thrombin cleavage site was introduced. The proper restriction
enzymes (Takara) and DH5a (RBC) competent cells were used to
clone the genes. Twenty-two decoy receptor variants with a single
substitution were constructed from the wild-type by site-directed
mutagenesis using overlapping PCR with proper primers [29].
Figure 4. Snapshots of molecular dynamics simulation trajec-
tories. Each snapshot was chosen to represent the changes in
interaction energies. (A) Modeled structure of the double mutant,
M41E/F63W. Increased hydrophobic environment resulting from the
F63W mutation induced strong charge interactions between Glu-41 of
the decoy receptor and Arg-68, Arg-69, and Lys-109 on MD2. (B)
Modeled structure of the double mutant, V134L/H159Q. The V134L
mutation led to increased hydrophobic interaction, strengthening the
charge interaction between Gln-159 on decoy receptor and Glu-111 on
MD2.
doi:10.1371/journal.pone.0030929.g004
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second and third mutations into single mutants. Each cell
containing the constructed mutant was cultured at 200 rpm in
LB media at 37uC overnight. After cell lysis, the DNA preparation
step was performed using a MIDI-preparation kit (Axygen) to
obtain a high DNA concentration (.1 mg/ml) for protein
expression using a baculovirus system.
Protein expression and purification
A baculovirus system with the recombinant transfer vector,
pAcGP67 (BD Biosciences) and Sf9 cells (Invitrogen) was used for
virus production and amplification of genes coding for wild-type
decoy receptor and the constructed mutants. A high DNA
concentration corresponding to the genes and linearized baculo-
virus DNA were co-transfected to the Sf9 cell. SF9 cells were used
for the virus amplification step. Hi5 cells (Invitrogen) were infected
with the harvested virus and cultured for 3 days at 28uC. Secreted
proteins were purified from the culture media using a column
packed with rProteinA Agarose 6FF (Peptron). Following a
washing step, the protein was subjected to thrombin digestion at
4uC overnight to remove the Fc tag. Wild-type decoy receptor and
its variants with no tag were collected from the flow-through of
resin. The mutant proteins were further purified using Q ion-
exchange and gel filtration chromatography (GE Healthcare Life
Sciences). Human MD2 fused to a protein A tag was co-expressed
with the wild-type decoy receptor or its mutants in Hi5 cells
followed by purification using a IgG Sepharose (GE Healthcare
Life Sciences) affinity chromatography. The protein A tag was
removed by thrombin digestion, and the MD2 complexed with
either wild-type decoy receptor or its mutants was further purified
using SP ion-exchange and gel filtration chromatography (GE
Healthcare Life Sciences). To remove an aggregated or multimeric
form of MD2, gel filtration chromatography using Superdex 75
was carried out using 20 mM Tris-Cl buffer (200 mM NaCl,
pH 8.0), and monomeric MD2 was used for further experiments.
The purification steps were performed at 4uC.
Surface plasmon resonance (SPR)
The binding affinities (KD) of the decoy receptor and its variants
with MD2 were obtained using SPR spectroscopy (Biacore 3000
System, GE Healthcare). Wild-type decoy receptor or its variants
were covalently immobilized onto a carboxymethyl dextran surface
of a CM5 chip using a standard EDC/NHS coupling method with
sodium acetate buffer (pH 3.5–4.5). The amount of protein
immobilized on the chip surface ranged from 500 to 800 resonance
units (RU). Serially diluted MD2 solutions with HBS-EP buffer (GE
Healthcare) were injected into the flow-cell at 60 mL/min for
90 sec, followed by a 30 min dissociation phase, and the changes in
RU were traced as a function of time. The MD2 concentration
ranged from 4 nM to 2 mM. Sensorgrams were corrected with a
blank reference and fit with Biacore Evaluation software. The KD
values were determined by fitting the data to a 1:1 Langmuir
binding model using Biacore Evaluation software.
Crystallization and structure determination
To determine the crystal structures of the decoy receptor
variants in complex with MD2, the complex crystals were obtained
in the presence of Eritoran, as described previously [23]. Eritoran
was a generous gift from Eisai (Andover, USA). Briefly, Eritoran
was sonicated for 10 min followed by incubation with the
preformed mutant/MD2 complex at 37uC for 3 hr. The molar
ratio of Eritoran to the protein was maintained at 10:1. The decoy
receptor variant /MD2/Eritoran complex was purified using
Superdex 200 gel filtration chromatography to remove unbound
Eritoran and used for crystallization. Crystals of the resulting
complexes were obtained by mixing 1 mL of protein solution and
1 mL of crystallization solution after 3 days at 23uC. The crystals of
the three variants were grown in 0.1 M Bis-Tris (pH 5.5)
containing 36% w/v polyethylene glycol 1000 and 0.2 M lithium
sulfate. The decoy receptor mutant/MD2/Eritoran complexes
were crystallized in 0.1 M sodium acetate (pH 4.5), 22% w/v
polyethylene glycol 8000, and 0.2 M lithium sulfate. For data
collection, ethylene glycol was included as a cryoprotectant in the
complex crystallization condition at a final concentration of 25%.
A diffraction data was collected using the synchrotron X-ray
source at the 4A beam line of the Pohang Accelerator Laboratory
(Pohang, Korea) and the BL-17A beam line of the Photon Factory
(Tsukuba, Japan). The diffraction images were processed with the
HKL2000 package and the MOSFLM/SCALA programs. Initial
phases were calculated by molecular replacement using PHASER
and refined with REFMAC 5.0 [30]. The crystal structures of the
decoy receptor alone (PDB ID 2Z62) and the decoy receptor/
MD2/Eritoran complex (PDB ID 2Z65) were used as the search
model. The molecular model was fit using the COOT graphic
program [31], and the final models were further refined using the
Phenix and CNS programs. Crystallographic and refinement
statistics are summarized in Table S2.
Modeling and simulation of variants
Modeled mutant structures were generated by searching a
rotamer library using FoldX BuildModel module [32,33] based on
the crystal structure of the wild-type decoy receptor/MD2/
Eritoran complex (PDB ID 2Z65) in pH 7 solution at 298 K. The
structures of five single variants (M41E, F63W, V134L, H159Q,
and D181E) and three double mutants (M41E/F63W, F63W/
D181E, and V134L/H159Q) were modeled. Because the
conformation of the MD2 Arg-68 on the F63W mutant was quite
different from that of the native structure, it was corrected to have
the native conformation by adjusting the torsion angles of Arg-68
and Trp-63 in PyMol (PyMOL Molecular Graphics System,
Version 1.2r3pre, Schro ¨dinger, LLC). Then, the system was
modeled with Amber03 force field [34] and simulated with the
Gromacs4 package [35]. In addition to the modeled structures, the
resolved crystal structures for the three mutants, M41E, F63W,
and V134L, were also used in simulations. The system was
solvated with TIP3P water molecules and neutralized by adding
chloride ions. We adopted the 5000 steps steepest decent energy
minimization process and subsequent 50 ps equilibration restrain-
ing the motion of heavy atoms for simulation. The system was
gradually heated from 0 to 310 K during 500 ps, and was
maintained at 310 K with Berendsen’s thermostat for 4.5 ns. The
last 3 ns trajectories were used for the analysis.
Trajectory analysis
Coulomb energy and the LJ potential between the residues of
mutants and MD2 were recalculated from the MD trajectory using
the ‘‘-rerun’’ option in mdrun of the Gromacs4 package. The
number of hydrogens for the same group was analyzed by the
g_hbond program in the Gromacs4 package.
Supporting Information
Figure S1 Binding affinities of the wild-type decoy
receptor and variants for MD2 by surface plasmon
resonance (SPR) measurements. (A)Wild-type decoy recep-
tor (B) M41E (C) F63W (D) V134L (E) M41E/F63W (F) V134L/
H159Q.
(TIF)
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